← All stocks

Tyra Biosciences, Inc.

TYRA Mostly scheduled

CIK 0001863127 #2234 in the set updated 17 Sep 2026

Bought (12 mo)

$20.00K

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$10.59M

$10.06M on a plan · $528.51K straight out of an exercise

Sold at will

$0.00

0 of 14 sales

Net

−$10.57M

+$20.00K against sales at will

By person

12 insiders · 15 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

MORE ROBERT J

Director

—

$5.25M (2) scheduled

−$5.25M

3,823,425

6.41%

$78.68M

−6.3%

Bensen Daniel

Chief Discovery Officer

—

$4.81M (11) scheduled

−$4.81M

146,981

0.2463%

$3.02M

−65.7%

KAPLAN GILLA

Director

—

$528.51K (1) scheduled

−$528.51K

28,231

0.0473%

$580.95K

−85.6%

Verjee Rehan

Director

$20.00K (1)

—

+$20.00K

972

0.0016%

$20.00K

—

RA CAPITAL MANAGEMENT, L.P. entity

Director

—

10,259,291

17.19%

$211.12M

+21.0%

Boxer Capital Management, LLC entity

See remarks

—

4,448,359

7.45%

$91.54M

−31.0%

Harris Todd

President and CEO

—

1,437,631

2.41%

$29.58M

−4.5%

Kjellson Nina S

Director

—

443,885

0.7438%

$9.13M

−37.4%

Rueb Yuliya

Vice President, Finance (PAO)

—

43,354

0.0726%

$892.16K

+23.8%

Fuhrman Alan

Chief Financial Officer

—

36,164

0.0606%

$744.20K

+979.8%

Warner Douglas J

Chief Medical Officer

—

25,000

0.0419%

$514.46K

—

Ashar Bhavesh

Chief Operating Officer

—

15,013

0.0252%

$308.94K

—

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 26

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 1

Sales on a Rule 10b5-1 plan 13

Sales straight out of an exercise 1

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 270,824

History held since 17 Sep 2021